Azathioprine, 6-mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety
- 1 September 2004
- journal article
- review article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 2 (9), 731-743
- https://doi.org/10.1016/s1542-3565(04)00344-1
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Predictive Factors of Response of Perianal Crohn's Disease to Azathioprine or 6-MercaptopurineDiseases of the Colon & Rectum, 2003
- Thiopurine S-methyltransferase genotyping does not predict azathioprine-induced myelosuppression in Crohn's diseaseGastroenterology, 2003
- No predictive value of TPMT genotyping for leukopenia or hepatotoxicity during azathioprine therapy in inflammatory bowel diseaseGastroenterology, 2003
- Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: A 2 year multicenter trialGastroenterology, 1998
- 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.Gut, 1996
- Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.Gut, 1996
- Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.Archives of Disease in Childhood, 1993
- Controlled trial of azathioprine in chronic ulcerative colitis.BMJ, 1982
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980
- A controlled trial of azathioprine in Crohn's diseaseDigestive Diseases and Sciences, 1975